Therefore, lumican’s anti-cancer effect in respect to the decrease of EGFR phosphorylation and the downregulation of the downstream signaling, which results in decreased phosphorylation of FAK and inhibition of cell migration, could be considered as a potential mechanism that needs further evaluation. The gene discussed is EGFR; the disease is cancer.